Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
GAITHERSBURG, Md., Oct. 19, 2016 -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will report its third quarter 2016 financial results after close of market on Monday, October 24, 2016. Following the announcement, OpGen’s management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the company’s financial results and business progress.
Dial-in Information
U.S. Dial-In Number: 844-420-8185
International Dial-In Number: 216-562-0481
Conference ID: 4676290
Replay Dial-In Information
U.S. Dial-In Number: 855-859-2056
International Dial-In Number: 404-537-3406
Conference ID: 4676290
The live, listen-only webcast of the conference call may also be accessed by visiting the investors section of the company’s website at http://ir.opgen.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company’s website for 90 days.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
Company Contact: Michael Farmer Director, Marketing (240) 813-1284 [email protected] [email protected] Investor and Media Contact: MacDougall Biomedical Communications Cammy Duong 781-235-3060 [email protected]
